Found: 24
Select item for more details and to access through your institution.
Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1990, v. 82, n. 17, p. 1397
- By:
- Publication type:
- Article
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
- Published in:
- BJU International, 2011, v. 108, n. 8b, p. E245, doi. 10.1111/j.1464-410X.2011.10096.x
- By:
- Publication type:
- Article
Biological drug duo delivers one-two tumor punch.
- Published in:
- Nature Medicine, 2003, v. 9, n. 6, p. 649, doi. 10.1038/nm0603-649
- By:
- Publication type:
- Article
Metastatic Renal Cancer Treated with Interleukin--2 and Lymphokine--Activated Killer Cells.
- Published in:
- Annals of Internal Medicine, 1988, v. 108, n. 4, p. 518, doi. 10.7326/0003-4819-108-4-518
- By:
- Publication type:
- Article
Interleukin-12, a New Anti-Tumor Cytokine.
- Published in:
- International Journal of Immunopathology & Pharmacology, 1998, v. 11, n. 3, p. 109, doi. 10.1177/039463209801100301
- By:
- Publication type:
- Article
Effects of Deoxycytidine on Mycoplasma-Associated Inhibition of Thymidine Incorporation and Growth in Antifolate-Containing Media.
- Published in:
- International Journal of Immunopathology & Pharmacology, 1988, v. 1, n. 2, p. 123, doi. 10.1177/039463208800100205
- By:
- Publication type:
- Article
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
- Published in:
- Molecular Cancer, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1476-4598-12-17
- By:
- Publication type:
- Article
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b<sup>+</sup>/Gr-1<sup>+</sup> myeloid derived suppressor cells.
- Published in:
- Molecular Cancer, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1476-4598-12-17
- By:
- Publication type:
- Article
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting <i>De Novo</i> Resistance Using BH3 Mimetics.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0101286
- By:
- Publication type:
- Article
Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0019144
- By:
- Publication type:
- Article
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 12, p. 1523, doi. 10.1007/s00262-016-1904-8
- By:
- Publication type:
- Article
Novel drugs that target the metabolic reprogramming in renal cell cancer.
- Published in:
- Cancer & Metabolism, 2016, v. 4, p. 1, doi. 10.1186/s40170-016-0154-8
- By:
- Publication type:
- Article
Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
- Published in:
- Molecular Cancer, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12943-021-01378-8
- By:
- Publication type:
- Article
Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
- Published in:
- Molecular Cancer, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12943-021-01379-7
- By:
- Publication type:
- Article
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
- Published in:
- Journal of Cellular & Molecular Medicine, 2013, v. 17, n. 3, p. 377, doi. 10.1111/jcmm.12019
- By:
- Publication type:
- Article
Malignant granular lymphoproliferation after Epstein-Barr virus infection: Partial immunologic reconstitution with interleukin-2.
- Published in:
- American Journal of Hematology, 1987, v. 25, n. 4, p. 427, doi. 10.1002/ajh.2830250409
- By:
- Publication type:
- Article
Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
- Published in:
- Nature Communications, 2016, v. 7, n. 8, p. 12624, doi. 10.1038/ncomms12624
- By:
- Publication type:
- Article
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 6, p. 1439, doi. 10.1007/s00280-011-1637-5
- By:
- Publication type:
- Article
Sunitinib activates Axl signaling in renal cell cancer.
- Published in:
- International Journal of Cancer, 2016, v. 138, n. 12, p. 3002, doi. 10.1002/ijc.30022
- By:
- Publication type:
- Article
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 5, p. 563, doi. 10.1002/ajh.25448
- By:
- Publication type:
- Article
Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference.
- Published in:
- 2009
- By:
- Publication type:
- Proceeding
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 617, doi. 10.1634/theoncologist.2015-0105
- By:
- Publication type:
- Article